Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02414139 · ClinicalTrials.gov registry record · Phase 2

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
373
Enrollment target
20
Study locations

NCT02414139 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 373 participants, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02414139, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
373 participants
Enrollment target
20
Study locations

Study Summary

Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK)-negative rearrangement, and mesenchymal epithelial transition (MET) mutations leading to exon 14 deletion (referred to as MET mutation hereafter) and/or MET amplification.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Capmatinib

Study Locations (20)

California

  • Pacific Shores Medical Group SC - Long Beach
  • University Of California Los Angeles Dept of Onc - Los Angeles
  • University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center - Orange

Other

  • Novartis Investigative Site - La Rioja
  • Novartis Investigative Site - Vienna
  • Novartis Investigative Site - Leuven

Pennsylvania

  • Lehigh Valley Health Network SC - Allentown
  • Andrew and Patel Associates - Camp Hill

Florida

  • H Lee Moffitt Cancer Center and Research Institute . - Tampa

Iowa

  • University of Iowa Hospitals and Clinics SC-3 - Iowa City

Massachusetts

  • Massachusetts General Hospital MGH Cancer Center - Boston

Michigan

  • VA Ann Arbor Health System VA Ann Arbor Health System - Ann Arbor

Minnesota

  • Mayo Clinic Rochester . - Rochester

Trial Details

FieldValue
Enrollment Target 373 participants
Start Date 2015-06-11
Est. Completion 2023-05-16
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02414139

The ClinicalTrials.gov registry entry for NCT02414139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (16% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Capmatinib is the first listed.

NCT02414139 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Other, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02414139 about?

NCT02414139 is a clinical study titled "Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)". Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations...

What is the current status of trial NCT02414139?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 373 participants. The study started on 2015-06-11. Estimated completion is 2023-05-16.

What conditions does trial NCT02414139 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT02414139?

The interventions under investigation include: Capmatinib (DRUG).

Who is sponsoring clinical trial NCT02414139?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02414139 being conducted?

This trial has 20 study locations across California, Florida, Iowa, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.